Enzymotec Ltd. (NASDAQ:ENZY) is set to issue its quarterly earnings data before the market opens on Tuesday, November 14th. Analysts expect the company to announce earnings of $0.10 per share for the quarter.
Enzymotec (NASDAQ:ENZY) last released its quarterly earnings results on Wednesday, August 16th. The biotechnology company reported ($0.10) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.05 by ($0.15). The firm had revenue of $13.00 million for the quarter, compared to analysts’ expectations of $12.78 million. Enzymotec had a negative net margin of 14.52% and a negative return on equity of 3.88%. The firm’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.04 EPS. On average, analysts expect Enzymotec to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Shares of Enzymotec Ltd. (NASDAQ:ENZY) opened at $11.80 on Monday. Enzymotec Ltd. has a 12-month low of $5.20 and a 12-month high of $12.35.
An institutional investor recently raised its position in Enzymotec stock. State Street Corp raised its position in Enzymotec Ltd. (NASDAQ:ENZY) by 1.8% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 20,952 shares of the biotechnology company’s stock after purchasing an additional 380 shares during the quarter. State Street Corp owned 0.09% of Enzymotec worth $169,000 as of its most recent SEC filing. 26.46% of the stock is currently owned by institutional investors.
Several research firms have recently commented on ENZY. Zacks Investment Research raised shares of Enzymotec from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 17th. ValuEngine raised shares of Enzymotec from a “sell” rating to a “hold” rating in a research report on Saturday, August 12th. Jefferies Group LLC reaffirmed a “hold” rating and set a $11.50 price target on shares of Enzymotec in a research report on Thursday, October 19th. Finally, Wells Fargo & Company boosted their target price on Enzymotec from $9.50 to $12.00 and gave the company a “market perform” rating in a research report on Monday, October 30th. Four research analysts have rated the stock with a hold rating, The stock presently has an average rating of “Hold” and a consensus target price of $11.75.
Enzymotec Company Profile
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.
Receive News & Ratings for Enzymotec Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.